Summarized by Masters of Longevity from PR Newswire.
Clinical coverage describing new conference-reported trial data on a TROP2-directed ADC plus PD-1 blockade as a first-line NSCLC treatment option; invites readers to see the presented results and implications.
Key Takeaways
- BAT8008 plus BAT1308 produced a 61.2% response rate in first-line NSCLC patients.
- The combination showed a median progression-free survival of 12.42 months overall.
- Treatment safety was manageable and no new safety signals were reported.
